| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3976743 | Brachytherapy | 2016 | 8 Pages |
Abstract
ISBT is a safe treatment for gynecologic malignancies. The dose to 0.1cc significantly predicts for severe urinary toxicity. Our data suggests that dose to a small urethral volume may be the most significant predictor of urinary toxicity in patients receiving ISBT for gynecologic cancer.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Mark J. Amsbaugh, Neal Bhatt, Thomas Hunter, Jeremy Gaskins, Lynn Parker, Daniel Metzinger, Ashley Amsbaugh, Keith Sowards, Moataz N. El-Ghamry,